Rogue Funds letter expresses frustration with Achieve Life Sciences, potential for significant upside

Rogue Funds released their first quarter 2025 investor letter, showing a 12.4% depreciation net of fees. Anticipating significant volatility in the near future, the fund’s concentration may lead to significant declines or rises in total returns. Check out the fund’s top 5 holdings for insights into their picks for 2025.

Achieve Life Sciences, Inc. (NASDAQ:ACHV) was highlighted in Rogue Funds’ Q1 2025 investor letter. With a one-month return of -43.08%, the stock lost 51.98% over the last 52 weeks. On July 3, 2025, ACHV stock closed at $2.18 per share, with a market cap of $108.314 million.

Rogue Funds expressed frustration with Achieve Life Sciences, Inc. (NASDAQ:ACHV) in their investor letter, citing the delay in NDA filing and expected positive results in July. Despite the current valuation being deemed ludicrous, the company is seen as undervalued with potential for significant upside in the future.

While Achieve Life Sciences, Inc. (NASDAQ:ACHV) is not on the list of 30 Most Popular Stocks Among Hedge Funds, 9 portfolios held the stock at the end of Q1. Rogue Funds sees greater promise in AI stocks for delivering higher returns in a shorter timeframe. For an undervalued AI stock with massive gains potential, check out their report.

Read more at Yahoo Finance: Should You Hold Achieve Life Sciences (ACHV)?